GlassScriptPhysician profile
Stephanie B Justus
NPI 1629452107
$6,121.47
in general payments reported to CMS, 2019-2025
53 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,202 · 2022: $854 · 2023: $1,519 · 2024: $1,498 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,060 · Education: $5.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,059.59 |
| Education | $5.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $780.54 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Neurocrine Biosciences, INC. | $577.40 | 2021-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $572.84 | 2021-2025 | |
| Pfizer INC. | $349.73 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $300.58 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Astellas Pharma US INC | $291.35 | 2021-2025 | Veozah |
| Abbott Laboratories | $290.46 | 2021-2025 | Freestyle Libre |
| Amgen INC. | $221.76 | 2021-2025 | Repatha, Otezla, Prolia |
| Janssen Pharmaceuticals, INC | $204.27 | 2021-2023 | Xarelto |
| Phathom Pharmaceuticals, INC. | $197.43 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.86 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $139.06 | 2021-2024 | Capvaxive, Gardasil, Vaxneuvance |
| Aimmune Therapeutics, INC. | $129.67 | 2024-2025 | Zenpep |
| Alkermes, INC. | $128.39 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $128.28 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Justus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.